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Objective: Living-donor lobar lung transplantation offers an alternative for 
patients with a life expectancy of less than a few months. We report on our 
intermediate results with respect to recipient survival, complications, 
pulmonary function, and hemodynamic reserve. Methods: Thirty-eight 
living.donor lobar lung transplants were performed in 27 adult and 10 
pediatric patients for cystic fibrosis (32), pulmonary hypertension (two), 
pulmonary fibrosis (one), viral bronchiolitis (one), bronchopulmonary 
dysplasia (one), and posttransplantation obliterative bronchiolitis (one). 
Seventy-six donors underwent donor lobectomies. Results: There were 14 
deaths among the 37 patients, with an average follow-up of 14 months. 
Predominant cause of death was infection, consistent with the large 
percentage of patients with cystic fibrosis in our population. The overall 
incidence of rejection was 0.07 episodes/patient-month, representing 0.8 
episodes/patient. Postoperative pulmonary function testing generally 
showed a steady improvement that plateaued by postoperative months 9 to 
12. Fourteen patients who were followed up for at least 1 year underwent 
right heart catheterization; pressures and pulmonary vascular resistances 
were within normal ranges. Bronchiolitis obliterans was definitively diag- 
nosed in three patients. Among the 76 donors, complications in the 
postoperative period included postpericardiotomy syndrome (three), atrial 
fibrillation (one), and surgical reexploration (three). Conclusions: We 
believe that these data support an expanded role for living-donor lobar lung 
transplantation. Our intermediate data are encouraging with respect to 
the functional outcome and survival of these critically ill patients, who 
would have died without this option. (J Thorac Cardiovasc Surg 
1996;112:1284-91) 
R ecent improvements in survival and quality of life have made pulmonary transplantation a 
therapeutic option for adults and children with 
end-stage lung disease, whether caused by parenchy- 
mal or by vascular lesions. 1-4 As a result of progress 
in this field, the number of patients waiting for lung 
transplants has grown, while the number of donors 
From the Division of Cardiothoracic Surgery, University of 
Southern California School of Medicine, Los Angeles, Calif. 
Read at the Seventy-sLxth Annual Meeting of The American Asso- 
ciation for Thoracic Surgery, San Diego, Calif., April 28-May 1, 
1996. 
Received for publication May 6, 1996; revisions requested June 
10, 1996; revisions received July 15, 1996; accepted for 
publication July 17, 1996.12/6/76551 
Address for reprints: Vaughn A. Starnes, MD, Professor and Chief, 
Division of Cardiothoracic Surgery, School of Medicine, 1510 
San Pablo St., Suite 415, Los Angeles, CA 90033-4612. 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/6/76551 
1284 
has remained relatively unchanged. According to 
the 1995 United Network for Organ Sharing 
(UNOS) Registry, s 1939 patients are waiting on the 
recipient list in the United States for lung transplan- 
tation, with the expectation that because of the 
donor shortage only 700 to 800 of these patients will 
receive transplants. The resulting mismatch between 
the growing number of recipients and the static pool 
of donors translates into an increasing number of 
deaths among patients on the waiting list. 
The concept of lobar transplantation was first 
developed as an alternative to whole-lung transplan- 
tation in children. 6The use of lobar transplantation 
made cadaveric adult donors available to small adult 
and pediatric recipients]' 8 Living-donor lobar lung 
transplantation offers an alternative form of treat- 
ment for patients who have a decline in physical 
status with a life expectancy of less than a few 
months or increasing risk with time of the develop- 
ment of an absolute contraindication to transplan- 
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tation. We report on the intermediate results with 
respect o recipient survival, complications, pulmo- 
nary function, and hemodynamic reserve. 
Patients and methods 
Recipient selection. From January 1993 to April 1996, 
38 bilateral living-donor transplants were performed in 37 
patients. Twenty-seven patients were adults, with a mean 
age of 25 years (range 18 to 36 years), and 10 were 
children, with a mean age of 13 years (range 9 to 17 years). 
There were 15 male and 22 female recipients. 
Recipients were selected on the basis of deteriorating 
status and the expectation that a cadaveric donor would 
not become available in time. Of the 37 patients who 
underwent ransplantation, 22 came from out of state, 
were transported on an emergency basis, and underwent 
transplantation within 72 hours of arrival. 
Most patients in our group were critically ill, as illus- 
trated by the number of those with marked weight loss, 
steroid dependence, increasing hypoxia or hypercapnia, 
increasing antibiotic resistance, deteriorating pulmonary 
function test values, recurring life-threatening pulmonary 
events (e.g., hemoptysis), and decreasing ability to per- 
form the activities of daily living (Table I). 
The indications for lobar transplantation were cystic 
fibrosis (n = 32), pulmonary hypertension (n = 2), 
pulmonary fibrosis (n = 1), viral bronchiolitis (n = 1), 
bronchopulmonary d splasia (n = 1), and posttransplan- 
tation obliterative bronchiolitis (n = 1). All patients 
fulfilled the criteria for cadaveric lung transplantation a d 
were listed with UNOS before lobar transplantation. 
Clinical deterioration without expectation of a cadaveric 
allograft was used as the criterion for entry into the 
living-donor lobar transplantation protocol. 
Absolute contraindications to lobar transplantation i - 
clude panresistant flora. Patients must have no significant 
irreversible nd-organ damage other than their pulmo- 
nary disease. Creatinine clearance studies are performed 
to assess renal status, especially for patients who received 
repeated courses of aminoglycosides. Echocardiographic 
assessment of left and right heart function is performed. 
Cardiac catheterization may be performed to determine 
pulmonary artery pressures. Seroligic testing includes 
cytomegalovirus; Epstein-Barr virus; hepatitis A, B, and 
C; toxoplasmosis; and human immunodeficiency virus; 
results are obtained at the time of evaluation. Bacterial 
infections, as demonstrated by an increasing white blood 
cell count, positive culture results, or fever, were treated 
before transplantation a d immunosuppression. 
Relative contraindications to lobar transplantation i - 
clude severe cachexia, pleural adhesions, diabetes, and 
long-term ventilatory support. A history of major thoracic 
surgery or pleurodesis is considered on a case-by-case 
basis. Patients with diabetes are considered if they have no 
other end-stage organ dysfunction. Patients receiving 
short-term ventilatory support are considered and un- 
dergo panculture to assess for infection before transplan- 
tation. Patients with decreased bone density are evaluated 
and may be placed on new prophylactic regimens. 
All patients must have the emotional and educational 
ability to undertake a major medical event and its se- 
Table I. Preoperative data, severity of illness 
In hospital 25/38 (66%) 
Preoperative steroids 19/38 (50%) 
Marked weight loss (% predicted) 76% 
Hypoxia 
Ventilator dependent, 1.00 Fio 2 6 
Bipap 3 
Hypercapnia 
PCO 2 (mm Hg) 69 (36-160) 
Mean FEV 1 (*% predicted) 19% (8%-30%) 
Fio2, Inspired oxygen fraction; Pco2, carbon dioxide fraction; FEV1, forced 
expiratory volume in 1 second. 
quelae. Ideally, the patient's upport structure should be 
identified before transplantation, because the people who 
form this structure are crucial throughout all the phases of 
transplantation. 
Donor selection. Initially, as per our original institu- 
tional review board protocol at the University of Southern 
California and Childrens Hospital Los Angeles, parents 
were the only donors used for living-donor lobar trans- 
plantation. This restriction limited the ability to offer this 
option to patients whose parents were not considered 
suitable donors because of results of diagnostic testing or 
age. Living-donor lobar transplantation was subsequently 
expanded to include all extended relatives and also unre- 
lated donors. The evolution was gradual and in conjunc- 
tion with the institutional review board. 
All potential donors evaluated have the knowledge and 
desire to pursue the option of donation. Preliminary 
testing includes ABO compatibility testing, chest radiog- 
raphy, and spirometry. Extensive psychosocial ssessment 
is performed by the transplant coordinator, social worker, 
and team psychiatrist. All donors and recipients are 
interviewed together to assess family dynamics and sepa- 
rately to avoid coercion. Preliminary screening allows a 
limited number of potential donors to be evaluated more 
fully, thereby decreasing costs. 
Potentially suitable donors undergo medical screening 
that includes the following: spirometry with arterial blood 
gas analysis, routine transplant serologic studies, sputum 
cultures, viral screening, electrocardiography, echocardi- 
ography, quantitative ventilation and perfusion scan with 
differential split and segmental analysis, and high-resolu- 
tion chest computerized tomography to exclude occult 
pathology and to make a volumetric assessment of the 
lobe to be removed. 
Seventy-six donors underwent donor lobectomies. They 
had a mean age of 40 years (range 18 to 55 years), a mean 
height of 170 cm (range 155 to 191 cm), and a mean 
weight of 71 kg (range 50 to 105 kg). Seventy-three donors 
were related to their recipients and three were unrelated. 
Operative procedures 
Donor lobectomy. In the removal of a healthy lobe for 
transplantation, the procedure must be conducted to 
avoid any compromise to the patient. The operation 
evolved with this premise in mind. The right lower lobe is 
removed as the graft for the right lung in the recipient and 
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the left lower lobe is removed as the left lung graft in the 
recipient. The right and left lower lobes have become the 
standard lobes removed. The anatomy of these lobes has 
permitted their removal with minimal complications in the 
donor and has provided adequate pulmonary reserve in 
the recipient. The complete details of the surgical tech- 
nique have been described elsewhere. 7 Before incision, 
the donors undergo preoperative bronchosc0py to assess 
for any occult disease and to determine bronchial anat- 
omy. This procedure resulted in the diagnosis of an 
endobronchial lesion in one patient, precluding donation 
at the time. Prostaglandin E 1 is administered intrave- 
nously to dilate the pulmonary vascular bed and the 
dosage is adjusted to maintain a systolic blood pressure of 
90 to 100 mm Hg. Several technical points should be 
emphasized. Manipulation of the lobe is kept to a mini- 
mum, fissures are developed with surgical staplers to avoid 
air leaks in both donor and recipient, and complete 
dissection of the bronchus, artery, and vein is performed, 
with their relationship to the remaining lobes noted 
before division. After the dissection is completed, heparin 
(300 U/kg) and methylprednisolone (Solu-Medrol) are 
given intravenously, followed by the division of the pul- 
monary artery, vein, and bronchus. This order of division 
is imPortant o avoid congestion of the lung graft. 
Donor lobe preservation. The lobe is removed and taken 
to a sterile back table. The pulmonary artery and pulmo- 
nary vein are alternately perfused with approximately 2 L 
modified Euro-Collins solution (4°C) until uniform 
blanching of the organ is achieved. The lobe is simulta- 
neously ventilated with room air to remove any areas of 
atelectasis. The bronchus is atraumatically clamped while 
the lobe is partially inflated, and the lobe is stored in cold 
saline solution (4 ° C) and transported to the recipient's 
operating room in an ice-filled cooler. The chest is closed 
in routine manner, and an epidural catheter is placed for 
administration of analgesics. The donor is moved to the 
Thoracic Intensive Care Unit. 
Recipient operation. At the same time that the two 
donor operations are being performed, the recipient 
operation is started in a third operating room. The 
recipient operation is conducted through a bilateral tho- 
racosternotomy (clamshell) incision, a Preliminary dissec- 
tion is carried out to free adhesions that might be present 
in the apical and diaphragmatic surfaces of the thorax and 
medially next to the pericardial surfaces. Once this dissec- 
tion is completed and bleeding is controlled, the patient is 
placed on cardiopulmonary bypass and the lungs are 
removed. In patients with cystic fibrosis, the chest is 
irrigated with tobramycin solution. Cardiopulmonary b - 
pass is employed for two reasons. First, the patients in this 
study were in such critical condition that single-lung 
ventilation could not be performed. Second, and most 
important, having all of the cardiac output driven through 
one lob e while the other lobe was being implanted would 
most likely result in reperfusion pulmonary edema. The 
cardiopulmonary b pass circuit is therefore used to allow 
simultaneous reperfusion of both lobes in a controlled 
fashion. 
The sequence of the recipient anastomosis i  the bron- 
chus, vein, and artery. The bronchial anastomosis is 
completed with running 4-0 polypropylene suture with 
minimal telescoping of the donor's lobe bronchus into the 
recipient's. By limiting the amount of peribronchial dis- 
section and using this technique of anastomosis, we have 
avoided bronchial complications. The pulmonary vein of 
the donor is anastomosed to the superior pulmonary vein 
of the recipient. The artery is anastomosed end-to-end 
with 5-0 polypropylene suture. At the conclusion of the 
transplant procedure, transesophageal echocardiography 
is performed to ensure that there are no technical com- 
plications with venous anastomosis. The mean ischemic 
time of the right lobe is 65.5 minutes (range 32 to 142 
minutes); that of the left lobe is 58.7 minutes (range 34 to 
112 minutes). 
Recipient postoperative management and immnnosup- 
press!on. Low-dose dopamine and dobutamine are used 
for Cardiovascular support as needed. The recipient is 
ventilated through a single-lumen tube with increased 
positive end-expiratory pressure of 5 to 10 mm H20 for 
approximately 48 to 72 hours. This prolonged ventilatory 
support is provided in an attempt o decrease atelectasis 
and maintain maximal expansion of the relatively under- 
sized lobes. In addition, we believe that this precaution 
may decrease reperfusion injury in this clinical setting, in 
which the entire cardiac output is flowing through only 
two lobes. Chest tube s are set to minimal suction during 
the first 12 to 24 hours. Several patients were difficult to 
ventilate if the chest ubes were set to the conventional 20 
cm H20. This problem is exaggerated when there is a 
large discrepancy between the sizes of the lobe and the 
thoracic avity. After the initial period of nil to minimal 
suction, increased suction is started on one tube at a time 
until all tubes are at 10 cm H20 suction. If this is 
tolerated, the tubes are then sequentially increased to 20 
cm H20 suction. The chest drains remain for a longer 
period (2 to 3 weeks) than with conventional cadaveric 
lung transplantation because of persistent serous drain- 
age, which is probably a result of the size and topographic 
mismatch of the lobe. A thoracic epidural catheter is 
placed when the patient is ready for extubation and after 
results of coagulation studies have returned to normal. 
A noninduction immunosuppressive protocol with cy- 
closporine, azathioprine, and prednisone was used for 
most Patients. Induction therapy with monoclonal or 
polyclonal antibodies has been avoided because of con- 
cerns with infection, especially in view of the large pro- 
portion of cystic fibrosis patients in our cohort. In 1995, 
use of the microemulsion formulation of cyclosporine 
(Neoral) was instituted because of its better absorption. 
FK 506 (Prograf) was also used in the three most recent 
patients. Before operation, the patient is given 2 mg/kg 
cyclosporine intravenously or 0.1 mg/kg FK 506 orally and 
is given 4 mg/kg azathioprine intravenously. During oper- 
ation, 15 mg/kg methylprednisolone is given after cardio- 
pulmonary bypass is terminated. After operation, 6 
mg.kg - I .  day -1 cyclosporine is given and the dose is 
adjusted to achieve a whole-blood level of approximately 
300 to 350 ng/ml. For those patients receiving FK 506, 
doses of 0.2 mg. kg -1 • day -1 are administered and ad- 
justed to achieve levels of 10 to 20 ng/ml. Azathioprine at 
a dose of 2 mg/kg/day is given and adjusted to achieve a 
white blood cell count of approximately 6000 cells/ram 3.
Corticosteroids are administered to achieve a prednisone 
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Fig. 1. Kaplan-Meier survival curve after live-donor lobar lung transplantation. 
IO74  
dose of 0.5 mg/kg/day by postoperative day 30. This dose 
is decreased by 0.1 mg- kg ~ • day -1 until the patient has 
reached a long-term maintenance dose of 0.1 mg to 0.2 
mg" kg 1. day-1. 
Pneumocystis carinii prophylaxis consists of tri- 
methoprim-sulfamethoxazole (320/1600 mg) given three 
times a week for the first year. Cytomegalovirus (CMV) 
prophylaxis given to all patients with a CMV-positive 
donor, regardless ofrecipient preoperative status. Prophy- 
laxis consists of 150 mg/kg CMV hyperimmune globulin 
intravenously on postoperative days 1 and 21. Ganciclovir 
is given intravenously at a dose of 6 mg/kg/day on post- 
operative days 14 through day 42. Acyclovir is given orally 
at 2400 rag/day thereafter for the first 6 months, as well as 
to all recipients with CMV-negative donors. 
Monitoring for infections and rejections is essentially 
the same as for cadaveric lung transplant recipients. 
Transbronchial biopsies are performed only when clini- 
cally indicated. 
Resu l ts  
There were 14 deaths among the 37 patients, 
with an average follow-up of 14 months (range 1 
to 34 months). The 1-year Kaplan-Meier survival 
was 68% (Fig. 1). Infection was the predominant 
cause of death, consistent with the large percent- 
age of patients with cystic fibrosis in our popula- 
tion (Table II). The incidence of infections was 
0.13 infections/patient-month, representing 1.6 in- 
fections/patient. Most infections resulting in mor- 
bidity and mortality were caused by Pseudomonas 
aemginosa (Table III). 
The overall incidence of rejection was 0.07 epi- 
sodes/patient-month, representing 0.8 episodes/pa- 
tient. Of the 30 episodes of rejection seen in the 37 
patients, 93% (28 episodes) were unilateral; only 
two episodes were bilateral and synchronous. Twen- 
ty-nine episodes (96%) were mild and classified as 
Table II. Causes of death (n = 14) 
Disseminated Aspergillosis 2 
Sepsis 2 
Pneumonia/sepsis 4 
Obliterative bronchiolitis 2 
Obliterative bronchiolitis/sepsis 2 
Renal failure, cerebral edema 1 
LAD thrombus 1 
LAD, Left anterior descending coronary artery. 
Table Ill. Infection 
Pseudomonas pneumonia 24 
Pseudomonas sepsis 2 
Staphylococcus pneumonia 4 
Symptomatic CMV 6 
Aspergillosis 5 
Candida bronchitis/pneumonia 3 
Other 6 
Total incidence 0.13 infections/patient-month, 1.6 infections/patients. 
grade A2 according to the International Society for 
Heart and Lung Transplantation grading system. 
There was only one rejection episode classified as 
grade A3. 
All episodes responded to an augmentation i
steroid dose. Four patients who had more than two 
episodes of rejection had additional therapy with FK 
506 as a replacement for cyclosporine and cyclo- 
phosphamide as a replacement for azathioprine, 
with or without the addition of methotrexate. 
The average number of HLA matches was 2.9, 
with a range of 0 to 6, and the average number of 
mismatches was 2.7, also with a range of 0 to 6. To 
date there has been no clear pattern in which lobe 
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Table IV. Postoperative pulmonary spirometric data 
Mean (%) Range (%) 
FVC 72 50-103 
FEV I 73 53-95 
DLCONA 87 52-103 
FEF25/75 92 74-150 
FVC, Forced vital capacity; FEV1, forced expiratory volume in 1 second; 
DLCO/VA, diffusing lung capacity corrected for alveolar volume; FEF25/75, 
mid-forced expiratory flow. 
will be rejected with respect o the HLA combina- 
tion. 
Postoperative pulmonary function testing gener- 
ally showed a steady improvement that plateaued by 
postoperative month 9 to 12. For the 15 patients 
with at least 1 year of follow-up, spirometric results 
were as follows: mean forced vital capacity was 72% 
predicted, mean forced expiratory volume in 1 sec- 
ond was 73% predicted, mean mid-forced expira- 
tory flow was 92%, and mean diffusing lung capacity 
corrected for alveolar volume was 87% predicted 
(Table IV). 
Because of the obvious concerns regarding 
whether pulmonary hypertension would develop in 
two lobes receiving apatient's entire cardiac output, 
14 patients who were followed up for at least 1 year 
underwent right heart catheterization. With the 
exception of one patient who was in her second 
trimester of pregnancy and another patient who had 
unilateral bronchiolitis obliterans with the majority 
of perfusion going to one lobe, the right heart 
pressures and pulmonary vascular esistances were 
within normal ranges. The results for all the patients 
studied are shown in Table V. 
There were two cases of posttransplant lympho- 
proliferative disease. Both cases responded to a 
decrease in immunosuppressive th rapy as the only 
therapy. 
Bronchiolitis obliterans was definitely diagnosed 
in three patients. One patient subsequently under- 
went another bilateral living-donor lobar lung trans- 
plant, whereas the other two patients died of their 
disease. Three additional patients were considered 
on clinical ground to have early bronchiolitis oblit- 
erans manifesting as a decrease in spirometric val- 
ues. Adjunctive treatment in these six patients in- 
cluded total lymphoid irradiation, methotrexate, 
ph0topheresis , antithymocyte ,/-globulin, mycophe- 
nolate mofetil, tacrolimus, and cyclophosphamide. 
With respect to the lifestyles of the surviving 
patients, 10 patients have returned to school, seven 
have returned to work, one is a new mother, and five 
Table V. Right heart catheterization results 
Mean Range 
RAP (ram Hg) 3 1-8 
PAP (mm Hg) 20 13-38 
PCWP (ram Hg) 9 2-19 
CO (L/min) 6.3 4.7-10.6 
PVR (wood units) 1.8 1.1-4 
n = 14 patients at 1 year follow-up. RAP, Right atrial pressure; PAP, 
pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; 
CO, cardiac output; PVR, pulmonary vascular esistance. 
are still within the first 6 postoperative months. All 
are in New York Heart Association functional class 
I or II. 
Donor outcomes are as important as recipient 
outcomes in living-donor lobar lung transplantation. 
Among the 76 donors, complications in the postop- 
erative period included postpericardiotomy s n- 
drome in three patients, atrial fibrillation in one 
patient, and surgical reexploration i three patients. 
The diagnoses of the three patients who underwent 
reexploration were sterile empyema (one), intercos- 
tal arterial bleeder (one), and a persistent air leak 
(one). All of the complications resolved without 
long-term sequelae. Postoperative spirometric test- 
ing of the donors demonstrated a 17% and 18% 
decrease in forced vital capacity and forced expira- 
tory volume in 1 second, respectively. This diminu- 
tion in pulmonary reserve resulted in no clinical 
impairment noted by the donors. In a retrospective 
questionnaire, 96% of the donors thought of the 
donation as a positive experience and would be 
willing to participate again. This survey included 
donors to recipients who died after operation. 
Discussion 
The donor pool is an ever-shrinking resource 
relative to the growing recipient list. As this discrep- 
ancy increases, more and more patients will die 
while on transplant lists waiting for a suitable cadav- 
eric donor. Living-donor lobar lung transplantation 
offers a workable alternative to some of these pa- 
tients when a cadaveric donor cannot be located. 
This report establishes living-donor lobar lung trans- 
plantation as a safe and reproducible procedure, 
with recipient outcomes comparable to those asso- 
ciated with cadaveric lung transplantation. The out- 
come data in this report were negatively skewed by 
severity of illness and the urgent nature of the 
transplant. Despite this adverse selection, out- 
comes for these 37 patients were comparable to 
the national cadaveric lung transplant statistics. 
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The 1-year survival of 68% for patients with cystic 
fibrosis among our living-donor transplant recipi- 
ents compares favorably with the national survival 
of 73%. 9 
Functional outcome is excellent, as demon- 
strated by normal hemodynamic and spirometric 
parameters measured at 1 year. Fourteen patients 
underwent right heart catheterization, which dem- 
onstrated normal right atrial pressures (mean 3.0 
mm Hg), normal cardiac output (mean 6.3 L/min), 
and normal pulmonary vascular esistance (mean 
1.8 wood units) These hemodynamic parameters 
were somewhat surprising, considering that the 
entire cardiac output is being distributed through 
two lobes. We believe that this confirms the 
adaptability of lobar transplantation with time. 
The spirometric data are equally impressive, with 
normal forced vital capacity (72% of predicted), 
forced expiratory volume in 1 second (73% of 
predicted), and diffusing lung capacity corrected 
for alveolar volume (mean 87% of predicted). The 
hemodynamic and spirometric data translate clin- 
ically to a picture of patients who are active with no 
restrictions on activities of daily living. Of the 23 
surviving patients, 22 are in New York Heart Associ- 
ation functional class L 
The complications noted in this group of pa- 
tients are comparable to those among patients 
receiving cadaveric lung transplants. The infection 
and rejection rates are not different from our 
cadaveric transplantation. 1° The pattern of rejec- 
tion, however, did differ. Of the 30 episodes of 
rejection seen, 93% (28) were unilateral; this 
differs from the cadaveric experience, where re- 
jection is normally bilateral. The rejection severity 
was less in the living-donor transplant group. Of 
the 29 episodes of rejection, 96% were mild and 
classified as A2 according to the International 
Society for Heart and Lung Transplantation grad- 
ing system. The rejection pattern for cadaveric 
lung transplantation has historically been more 
severe. These differences in rejection noted are 
not explained by the HLA matches and mis- 
matches. In a comparison of unilateral versus 
bilateral rejection, the number of HLA matches 
and mismatches are seen to be the same in the 
rejecting and nonrejecting lobes. Obliterative 
bronchiolitis has remained a problem in living- 
donor lobar lung transplantation, asit has been in 
cadaveric lung transplantation. Three patients 
(8%) had tissue confirmation of obliterative bron- 
chiolitis and three additional patients are sus- 
pected to have obliterative bronchiolitis on the 
basis of spirometry. In comparison, obliterative 
bronchiolitis rates in cadaveric lung transplant 
recipients average between 20% and 35%, so the 
combined rate of 16% (confirmed and suspected) 
compares favorably, n' 12 
In summary, living-donor lobar lung transplanta- 
tion is a workable option for patients whose condi- 
tions are deteriorating or who are acquiring charac- 
teristics that would make them unsuitable candidates 
for cadaveric lung transplantation. These intermedi- 
ate data are encouraging with respect o the func- 
tional outcome and survival of these critically ill 
patients, who would have died without this option. 
The question of whether this operation should be 
expanded to more elective situations requires more 
data. Because of the risk to the donor, the weight of 
the argument still favors living-donor transplanta- 
tion only for the patient in clinically deteriorating 
condition. We believe that the data presented here 
support an expanded role for living-donor lobar 
lung transplantation. 
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Discussion 
Dr. Charles B. Huddleston (St. Louis, Mo.). This really 
is pioneering work, and you should be congratulated for 
an excellent presentation. In addition, I think that the 
thoracic surgeons at USC owe you a debt of gratitude for 
the opportunity of performing operations on 76 healthy, 
nonsmoking persons without cancer or emphysema. 
We have had some experience with this procedure in 
children at St. Louis, although amuch smaller one (just six 
children), with one death at a mean follow-up of 1 year 
after transplantation. Our posttransplantation results are 
fairly similar to yours. We have not had a patient riding a 
motorcycle, but we did have one on page 2 of the National 
Enquirer. 
One would hope that, as with renal transplants, living- 
donor transplants of the lung would in fact have better 
long-term results than would cadaveric donor transplants. 
To date, unfortunately, that has not occurred. The pre- 
transplant condition of the recipients, however, may play 
an important role in this result. Our biggest problem with 
this procedure is really in deciding how to apply it. At 
present, our candidates are patients already listed for lung 
transplantation who are in deteriorating condition and for 
whom we estimate survival to be only 2 weeks. All six of 
our recipients have been on the ventilator, paralyzed, with 
an inspired oxygen fraction of 80% to 100% to maintain 
physiologic blood gas values. Most of them have also 
required inotropic agents to support heir blood pressure. 
Our reluctance to expand this procedure beyond those 
who are truly desperately ill is primarily a result of the 
morbidity imposed on the donors by a thoracotomy and a 
lobectomy. The somewhat unpredictable nature of cadav- 
eric availability also plays a role in this. 
I note that a large portion of your patients were in fact 
outpatients at the time that they came for their living- 
donor lobar lung transplant, and I wonder if you could be 
more specific about the pretransplant condition of these 
recipients, particularly those who are outpatients. I think 
that you answered this in your presentation tosome extent 
already. My next question pertains to the size mismatch. 
All six of our recipients were children and were much 
smaller than the donors that were available. The calcu- 
lated lung volumes that the recipient received actually 
matched closely with the predicted forced vital capacity 
and the forced expiratory volume in 1 second for the 
recipient according to their height. A recent patient whom 
we evaluated, however, was in fact taller than all of the 
prospective donors, and we have had some reluctance to 
transplant to him from living donors because of that. Have 
you in fact turned down any patients for whom you 
thought that the prospective donors were too small? 
Finally, although all of your patients had bilateral trans- 
plants, would you consider a single-lobe lung transplant in 
a patient, appropriately matched with a prospective do- 
nor, who has pulmonary fibrosis or pulmonary hyperten- 
sion and for whom a second prospective donor could not 
be found? 
Dr. Starnes. In looking at the recipients who were 
outpatients rather than the patients in acute, deteriorating 
condition, most of these patients were developing panre- 
sistant organisms. We know that panresistant infection is 
a high-risk factor for the patient undergoing conventional 
cadaveric lung transplantation. I have to say that all 
patients were reaching a deteriorating status; they were in 
and out of the hospital for frequent hospitalizations and 
treatment of their infections. As I pointed out, 25 of the 37 
patients were actually in the hospital and in deteriorating 
condition at the time of transplantation. 
With respect o the size mismatch, I think that this is 
still an inexact science. We transplanted one mismatched 
case where the recipient was actually 4 to 5 inches taller 
than the donor. One problem that you get into, as I tried 
to discuss in the article, is that you have trouble in the 
acute phase with suction of the chest drains. We found 
that we cannot initially use any suction. After about 24 
hours, you can start applying suction. We found that if we 
applied suction acutely we could not ventilate the patient. 
It is almost as though they pull out their lungs to the 
maximal residual capacity, and you just cannot move the 
lungs. That is one caveat hat we have learned with large 
size mismatches. Another factor is that the recipient does 
have drainage for a prolonged period when you have a 
substantial mismatch. In some of our cases with greater 
discrepancies, we have had chest drains in for 30 or 35 
days, draining 300 to 400 ml/day. The question is whether 
you can just pull those tubes; as with any lobectomy, or 
even pneumonectomy, there is obligatory space filling of 
the area with fluid. Because of the concerns of compres- 
sion of the recipient lung, however, we have not been 
willing to do that. 
Would I be willing to consider a unilateral obar 
transplant? I think the answer is yes. Actually, the first 
transplant hat I did, when I was at Stanford, was a 
unilateral transplant in a 10-year-old with pulmonary 
fibrosis. The donor was the mother, from whom I removed 
the right upper lobe. I think that if I were doing a 
unilateral transplant, however, I would probably make 
sure that the pulmonary artery pressures were not excep- 
tionally high. I think that trying to put all of the cardiac 
output through one lobe would be a substantial problem. 
Dr. Thomas M. Egan (Chapel Hill, N.C.). Dr. Hud- 
dleston actually raised two of the issues that I wanted to 
address. Number one, what is your size limit? I mean, 
have you ever said to somebody, "No, we cannot do this 
because you are too big and your donors are too small"? 
That is a problem that we have run into with adult patients 
with cystic fibrosis. Second, with respect o the recipients 
who were outpatients, you mentioned increasing antibi- 
otic resistance as an indication. Have you ever performed 
a transplant in a patient who had cystic fibrosis and 
panresistant flora, and have you performed on or offered 
this operation to patients who are colonized with Burk- 
holderia cepacia? 
Dr. Starnes. Taking the last questions together, we have 
not performed a transplant on a patient with panresistant 
organisms or with B. cepacia, because we think that these 
factors negatively affect outcomes to a substantial degree. 
We have turned down patients because we thought hat 
the recipient was just too big for the respective donors. 
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We have had some people calling with emphysema, for 
example, for whom I think that it is inappropriate. We 
have transplanted in the case of a size discrepancy of 4 to 
5 inches in height, knowing that we would have substantial 
acute and chronic problems with chest drainage, but we 
have done that only when the patient was truly in a 
life-threatening situation. 
Dr. Otto Gago (Ann Arbor, Mich.). I congratulate you 
on your outstanding work in this field, but I also pay 
tribute to Dr. William Adams, who was chairman of the 
Department ofSurgery at the University of Chicago in the 
early 1960s, and to the group of surgeons doing funda- 
mental work with a similar idea in pulmonary and lobar 
transplantation. The results of some of that work were 
presented on several occasions and subsequently pub- 
lished in the Journal (1964;40:726, 1965;50:775, and 1967; 
53:109). 
I also have a question regarding the indications of 
patients with pulmonary hypertension. What is your limit 
with respect o the pulmonary artery pressure and resis- 
tance? Also, would you do a unilateral or bilateral lobar 
lung transplantation, and do you use a cardiopulmonary 
bypass ystem in those cases? 
Dr. Starnes. We used cardiopulmonary b pass in all of 
these patients. We believe that it is important to allow 
reperfusion in a controlled fashion. We actually remove 
these patients from the heart-lung machine in a slightly 
hypovolemic state to avoid acute reperfusion of the lungs 
as much as possible. Most of these patients have acute 
pulmonary artery pressures of at least a third to even 
sometimes a half systemic. In terms of whom I would 
consider for transplantation with pulmonary hyperten- 
sion, we have done this in two cases. Both patients were 
children, age 12 and 13 years, and we have only done 
bilateral lobar transplants. I would not consider a unilat- 
eral lobar transplant for a patient with pulmonary hyper- 
tension because I believe the pulmonary vascular reserve 
is inadequate in that situation. 
Dr. Michael Bonsamra (Milwaukee, Wis.). I congratu- 
late you on your pioneering work, which both offers a 
viable alternative to patients who are nearing death with 
end-stage lung disease and also partially alleviates the 
donor supply problem. I am concerned, however, that the 
procedure may be being applied too liberally. 
I have two questions. During the time that you per- 
formed living related-donor bilateral lung transplants for 
patients with cystic fibrosis, how many cadaveric trans- 
plants did you perform? Second, what was the mortality 
for your patients with cystic fibrosis on the waiting list at 
that time? 
Dr. Starnes. During the concurrent time, we performed 
10 cadaveric lung transplants for patients with cystic 
fibrosis. The death rate of patients on our waiting list has 
been around 15% to 20%. 
Regarding the overly liberal use of this operation, I 
think that we have not done that. I think we always take 
into consideration that we have three patients, two of 
which are healthy adults, and I believe that the operation 
is still appropriate for patients who have no other alter- 
native. 
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